Hypofractionated carbon ‐ion radiotherapy for stage I peripheral nonsmall cell lung cancer (GUNMA0701): Prospective phase II study

The aim of this phase II study was to confirm the feasibility and safety of hypofractionated carbon ‐ion radiotherapy for patients with stage I peripheral nonsmall cell lung cancer. The actuarial 2‐year and 5‐year local control rates were 91.2% and 88.1%, respectively. The actuarial 2‐year and 5‐year overall survival rates were 91.9% and 74.9%, respectively. AbstractThis phase II study's aim was to confirm the efficacy and safety of hypofractionated carbon ‐ion radiotherapy in patients with stage I peripheral nonsmall cell lung cancer (NSCLC). The study encompassed 37 patients with histologically proven peripheral stage I NSCLC in the period June 2010‐March 2015. All underwent the planned full dose of carbon‐ion radiotherapy, administered with r elative biological effectiveness of 52.8 Gy and 60 Gy (divided into four fractions over 1 week) for T1 and T2a tumors, respectively. The 2‐year local control rate was set as the primary endpoint, while overall survival, progression‐free survival, and the incidence rates of acute and late adve rse events were secondary endpoints. The patients were followed up for 56.3 months overall and 62.2 months in the surviving patients, respectively. The actuarial local control rates were 91.2% after 2 years, and 88.1% after 5 years. No differences were found between the T1 and T2a tumors in the 5‐ year local control rate (90.9% vs 86.7%,P = .75). The actuarial overall survival rates achieved 91.9% for 2‐year and 74....
Source: Cancer Medicine - Category: Cancer & Oncology Authors: Tags: ORIGINAL RESEARCH Source Type: research